Article
Oncology
Felix Ehret, David Kaul, Lucas Mose, Volker Budach, Peter Vajkoczy, Christoph Fuerweger, Alfred Haidenberger, Alexander Muacevic, Felix Mehrhof, Markus Kufeld
Summary: This study aimed to assess the incidence of intracranial hemorrhage (ICH) in patients with brain metastases (BM) who are receiving therapeutic anticoagulant therapy (ACT) and undergoing stereotactic radiosurgery (SRS). The results showed that ICHs mostly occurred in patients with BM originating from malignant melanomas and with signs of ICH before SRS treatment. Overall, ACT and single-fraction SRS did not seem to pose a clinically relevant risk of ICH in patients with small- to medium-sized BM.
Article
Oncology
Lauren Reed-Guy, Arati S. Desai, Richard E. Phillips, Desiree Croteau, Karen Albright, Meghan O'Neill, Steven Brem, Donald M. O'Rourke, Nduka M. Amankulor, Stephen J. Bagley
Summary: DOACs are associated with a lower incidence of clinically relevant ICH in patients with GBM-associated VTE compared to LMWH.
Article
Cell Biology
Hakon S. Johnsen, Sigrid K. Braekkan, Vania M. Morelli, John-Bjarne Hansen
Summary: The study indicates that increasing platelet count in patients with VTE is associated with a higher risk of major bleeding. This association is observed not only with platelet count at VTE diagnosis, but also with platelet count measured on average 7 years before the thrombotic event.
Article
Hematology
Sirui Ma, Rushad Patell, Eric Miller, Siyang Ren, Josue Marquez-Garcia, Samuel Panoff, Ria Sharma, Amanda Pinson, Pavania Elavalakanar, Grif fin Weber, Erik Uhlmann, Donna Neuberg, Salil Soman, Jeffrey I. Zwicker
Summary: This study found no increased risk of intracranial hemorrhage in patients with primary brain tumors exposed to antiplatelet medications, based on a matched retrospective cohort study.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Review
Hematology
Johnathon Gorman, Matteo Candeloro, Sam Schulman
Summary: This study retrospectively analyzed all cases of VTE diagnosed during hospitalization for spontaneous ICH at our center over a 15-year period. The results showed that prompt therapeutic anticoagulation for acute VTE seems safe when occurring more than 14 days after spontaneous ICH. For VTE occurring earlier, stepwise dose escalation to therapeutic within a 7-day period might be preferable.
THROMBOSIS AND HAEMOSTASIS
(2023)
Review
Medicine, General & Internal
Philipp Buecke, Victoria Hellstern, Alexandru Cimpoca, Jose E. Cohen, Thomas Horvath, Oliver Ganslandt, Hansjoerg Baezner, Hans Henkes
Summary: This systematic review examines the use of endovascular treatment (EVT) for cerebral venous sinus/vein thromboses (SVT), focusing on patient selection, treatment strategies, and the impact of the COVID-19 pandemic. The study found that EVT was feasible and safe in a highly selected patient cohort, but did not lead to increased favorable functional outcomes according to randomized controlled trial (RCT) data. However, observational data showed frequent good functional outcomes despite an anticipated poor prognosis. Further research is needed to identify high-risk patients, determine optimal methods and devices, and establish best timing for treatment initiation.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Oncology
Maria Diaz, Jasmin Jo
Summary: Brain tumor patients have a higher risk of VTE, and recent studies have identified new risk factors and molecular mechanisms associated with VTE in these patients. Anticoagulation is necessary for VTE treatment in brain tumor patients, and DOACs may be a feasible option.
CURRENT ONCOLOGY REPORTS
(2022)
Article
Clinical Neurology
Thuhien Nguyen, Monisha Sharma, Patrick Crooks, Pratik Patel, Robert H. Bonow, Claire J. Creutzfeldt, Sarah Wahlster
Summary: This study aims to assess the risk of hematoma expansion in patients with acute intracranial hemorrhage (ICH) who require therapeutic anticoagulation for venous thromboembolism. The retrospective study included 50 patients and found that 12% of them developed hematoma expansion during the treatment, with a mortality rate of 4%.
BRITISH JOURNAL OF NEUROSURGERY
(2022)
Article
Dermatology
Dana Westphal, Matthias Meinhardt, Konrad Gruetzmann, Lisa Schoene, Julian Steininger, Lena T. Neuhaus, Miriam Wiegel, Daniel Schrimpf, Daniela E. Aust, Evelin Schroeck, Gustavo B. Baretton, Stefan Beissert, Tareq A. Juratli, Gabriele G. Schackert, Jan Gravemeyer, Juergen C. Becker, Andreas von Deimling, Christian Koelsche, Barbara Klink, Friedegund Meier, Alexander Schulz, Michael H. Muders, Michael Seifert
Summary: This study integrated omics data analysis to evaluate the methylomes and transcriptomes of matched melanoma metastases, identifying 38 candidate genes with distinct promoter methylation and gene expression changes in intracranial compared with extracranial metastases. The protein expression of the 11 most promising genes was validated using immunohistochemistry, and significant differences were observed in intracranial metastases. Knockdown of PRKCZ or GRB10 altered protein kinase B expression and decreased the viability of a brain-specific melanoma cell line. These findings provide insights into the molecular mechanisms that differentiate brain metastases and could be targeted for therapy.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2023)
Article
Medicine, General & Internal
Quanhong Chu, Lin Liao, Wenxin Wei, Ziming Ye, Li Zeng, Chao Qin, Yanyan Tang
Summary: The study found that malignancy, pulmonary circulation disease, coagulopathy, age >60 years old, and hospitalization time >16 days are independent risk factors for VTE in ICH patients, and anticoagulation therapy for VTE in ICH patients may be safe and effective. These findings need to be verified by more high-quality and well-designed randomized controlled trials.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
(2021)
Article
Oncology
Andrew W. Swartz, Jan Drappatz
Summary: This study found that patients with brain tumors using DOACs experienced fewer major bleeding events compared to those using LMWH, with similar efficacy, suggesting that DOACs are a safe and effective treatment option for these patients.
Article
Hematology
David Spirk, Tim Sebastian, Stefano Barco, Martin Banyai, Juerg H. Beer, Lucia Mazzolai, Thomas Baldi, Drahomir Aujesky, Daniel Hayoz, Rolf P. Engelberger, Thomas Kaeslin, Wolfgang Korte, Robert Escher, Marc Husmann, Marc Blondon, Nils Kucher
Summary: In patients with cancer-associated venous thromboembolism (VTE), the risk of recurrence is similar after incidental and symptomatic events. It is unknown whether the same applies to incidental VTE not associated with cancer. After comparing baseline characteristics, anticoagulation therapy, all-cause mortality, and VTE recurrence rates at 90 days between patients with incidental and symptomatic VTE, the study found that receiving anticoagulation therapy for at least 3 months was associated with lower mortality and recurrence rates in patients with incidental VTE regardless of cancer status. Additionally, among noncancer patients, early mortality and recurrence rates were similar after incidental versus symptomatic VTE.
THROMBOSIS AND HAEMOSTASIS
(2021)
Review
Cell Biology
Viktoria Muster, Thomas Gary
Summary: Glioblastoma patients have a high risk of developing venous thromboembolism, making therapeutic anticoagulation challenging with limited data available for this vulnerable patient group.
Review
Oncology
Lai Heng Lee, Pongwut Danchaivijitr, Noppacharn Uaprasert, Harinder Gill, Dennis Lee Sacdalan, Gwo Fuang Ho, Rajiv Parakh, Paresh Pai, Jen-Kuang Lee, Nannette Rey, Alexander T. Cohen
Summary: Direct oral anticoagulants (DOACs) have shown comparable efficacy and safety outcomes in Asian patients with cancer-associated thrombosis (CAT) compared to other races. Apixaban, edoxaban, or rivaroxaban can be considered as reasonable alternatives to low-molecular-weight heparin (LMWH) for anticoagulation in Asian patients with CAT.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Review
Hematology
Camille Simard, Lindsey Gerstein, Teresa Cafaro, Kris B. Filion, Antonios Douros, Isabelle Malhame, Vicky Tagalakis
Summary: Among pregnant women receiving therapeutic anticoagulation for VTE, the reported bleeding risk varies greatly, and more large-scale studies with standardized bleeding definitions are needed to optimize patient care.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS
(2022)
